Piramal Healthcare to present Phase I clinical data for oral anticancer molecule

22 May 2012 Evaluate

Piramal Healthcare will present its Phase I clinical trial data for its investigational new drug candidate P1446A-05 at the Annual Meeting of the American Society for Clinical Oncology (ASCO) being convened in Chicago from June 1-5, 2012. This year’s ASCO meeting will bring together more than 34,000 participants from around the world and will focus on the theme of collaborating to Conquer Cancer.

The two posters from Piramal Healthcare and participating investigators to be discussed on June 2, 2012, in the Developmental Therapeutics- Expiremental Therapeutics session, will report results of Phase I Clinical studies for P1446A-05 conducted in India and Canada, each investigating two different closing schedules.

P1446A-05 is a potent inhibitor of cyclin dependent kinases (Cdks) which are enzymes that regulate the cell cycle. Dysregulation of the cell cycle is often observed in human malignancies which derive malignant growth and unbalances the normal balance between cell division and death.

P1446A-05 will be the second molecule in Piramal’s oncology pipeline to enter Phase II trials. The first molecule P276 is in Phase II/III trials for multiple indications of cancer.

Piramal Enterprises Share Price

1099.50 5.85 (0.53%)
23-Dec-2024 13:09 View Price Chart
Peers
Company Name CMP
Bajaj Finance 6905.20
Shriram Finance 2881.90
Aditya Birla Capital 187.20
SBI Cards AndPayment 694.15
Mah & Mah Finl. Serv 266.25
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.